Abid Ansari Email & Phone Number

Raleigh, NC, US

Durham, NC, US

Series A start up responsible for advising on investor relations, finance, marketing, and operations

Rockville, Maryland, US

Cambridge, GB

• Led the $153M Series C executed in July 2021 including generation of >$270M in demand
• Restructured finance team in preparation for transition from private to public company, achieved SOX404 compliance
• Led the implementation of portfolio prioritization methodology, yielded adjustments to clinical development strategy

Durham, North Carolina, US

• Led the $146M IPO executed in April 2019, the largest pre-clinical Biotech IPO of the year
• Represented company at over 15 health care conferences including corporate presentation and investor engagements
• Raised over $200M including $110M Series B, $40M Convertible Note, and $30M Line of Credit Facility
• Grew the finance, operations, and IT teams from 4 employees to 35. Development of teams yielded 12 employee promotions and resulted in successful transition from private to public company
• Responsible for $26M, 53K square feet of expansion over 3 sites all on time and on budget

Brentford, Middlesex, GB

• Deal finance lead in R&D World Wide Business Development for six executed deals including
• Business acquisition of BMS HIV portfolio for up to $1.4B in total consideration + royalties
• Divestment of ofatumumab autoimmune indications to Novartis for up to $1B + royalties
• In-license/option cell and gene therapy deal with Miltenyi Biotech
• In-license/option cell and gene therapy deal with Adaptimmune
• In-licensed technology deal with Palantir Deals total ~£700M+ in upfront payments, ~£2.2B+ in development/sales milestones, and royalties on net sales. Also Deal Finance Lead for non-executed VC backed spin-out of 4.

Brentford, Middlesex, GB

• Led a global team of 4 (2 Directors - US, 2 Managers - UK) responsible for investment analytics/decision making support for senior management & product development teams.
• Key contributor to valuation of GSK R&D pipeline including negotiation with UK/US Tax authorities on approach; resulted in 2.5% reduction in overall GSK effective corporate tax rate
• Overall Annual Portfolio Investment Board planning lead including development of key analytics used to optimize ROI for R&D on ~£1B in external spend
• Business liaison member on Pipeline Progression Team presenting key results on PH IIIB/IV, long range forecast and candidate selection quality. Resulted in implementation of initiatives to improve pipeline.

Gaithersburg, Maryland, US

• Led the formation of the Global MedImmune Capital Finance Group (1 Sr. Manager, 1 Sr. Accountant) responsible for >$200M in annual capital spend across R&D, Manufacturing, and Commercial
• Published guidelines and accounting policies for MedImmune Capital Investment Life Cycle Management initiative
• Presented business case analysis/justification for significant capital investments ultimately approved by senior leadership
• Achieved MET level agreement of long range operating plan through development of portfolio prioritization scoring system/analytics
• Capital SAP lead for Investment Management & Project Systems integration into AstraZeneca North American Platform

Gaithersburg, Maryland, US

• Portfolio Analytics lead responsible for development of analytics used to optimize investments in R&D.
• Presented key pipeline results to MET through development of revenue and cost analytics for the long range operating plan.
• Led the development of portfolio optimization analytics to prioritize biologic programs given a set of business constraints; rankings of small molecules and biologics achieved through financial/technical harmonization.
• Achieved consensus on MedI-545 global forecast through two-day summit with AZ country presidents in London

Gaithersburg, Maryland, US

• Responsible for P&L management of FluMist Franchise (Sales of ~$150M/Year) including S&M costs (~$20M/Year). Led hiring/development of one Sr. Analyst.
• Next generation FluMist program (Quadrivalent Flu Vaccine) approved through key decision tree analytics/simulations presented to CEO.
• Responsible for long range operating plan, forecasts, and accounting treatment (including gross to net) of FluMist Brand and Sales Organization
• Responsible for financial/strategic/accounting input on FluMist Ex-US team
• Led the close process and variance analysis for FluMist and various Sales Departments
• Developed/integrated accounting policy and transaction process to support sublicense/license use of Reverse Genetics Technology with Sanofi, GSK, Novartis and CSL.

• Led a team of 4 (Sr. Analyst, Two Accountants, Payroll Clerk) responsible for specialty chemicals manufacturing site delivering ~$200M per year in sales.
• Part of M&A transition team which resulted in the £410M sale of Uniqema to Croda Chemicals
• Led the negotiation and completion of new $8M service level agreement with SPI Polyols and FujiFilm
• Led documentation introduction and implementation for finance/accounting processes; SOX Unit Champion for site
• Led the consolidation, headcount reduction, capability improvement of Atlas Point Finance Function
• Developed new standard costing tools for $90 mm batch process; yielding on-going conversion savings of ~$4.0 mm/yr

US

B.S. Chemical Engineering

Accounting Minor, Cpa-Delaware

Mba, Finance And Operations Management